Announcement
03 Jun 2024
In June 2024, US BARDA awarded USD 33.8 million to CastleVax USA to support the planning and potential execution of a Phase 2b clinical trial for their novel COVID-19 vaccine candidate.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
03 Jun 2024
Revocation date:
No revocation date
Updated: 03 Jun 2024
State aid, unspecified
In force
On 3 June 2024, the Biomedical Advanced Research and Development Authority (BARDA) provided USD 33.8 million in funding to CastleVax to develop their NDV-HXP-S vaccine, which uses a Newcastle disease ...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.